Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
The free software community has always thwarted the toughest challenges facing freedom in technology. This winter season, we want to thank the many individuals and projects that have helped us get ...
1. Risk: AI Monoculture (Shared Blind Spots). This is the most critical and overlooked systemic vulnerability. Building your ...
One of the most significant insights from the study is that roboticists must engage both technically and physically with ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback